Zhi Tong Cai Jing·2026-01-20 13:36Group 1 - GSK has agreed to acquire RAPT Therapeutics for a total valuation of $2.2 billion, with RAPT's stock price rising nearly 64% to $57.40 following the announcement [1] - GSK will pay RAPT shareholders $58.00 per share, leading to an expected upfront investment of $1.9 billion after deducting cash from the acquisition [1] - The acquisition is expected to be completed in the first quarter of 2026 and will be recorded as a business combination by GSK [1] Group 2 - GSK will gain global rights to the ozureprubart project, excluding certain regions in Greater China, and will be responsible for milestone payments and royalties to RAPT's partner, Shanghai Jeyou Pharmaceutical Co. [2] - GSK's Chief Scientific Officer, Tony Wood, highlighted ozureprubart as a promising new therapy with "best-in-class" potential, offering long-lasting protection for food allergy patients with a dosing schedule of every 12 weeks, compared to existing therapies that require biweekly injections [2]